Skip to content

News

New Bioinformatics Tool Shows Promise for Matching Cancer Patients with Optimal Treatment Combinations

New Bioinformatics Tool Shows Promise for Matching Cancer Patients with Optimal Treatment Combinations

Recent OCRA-funded research has resulted in the creation of a new bioinformatics tool that holds potential for predicting the best treatment combinations for cancer patients.  Bioinformatics is a scientific discipline that enables researchers to collect, process and analyze a vast amount of biological and medical data via computers and statistical techniques. In the case of … Continued

Sandra Cascio, PhD | Meet a Scientist

Sandra Cascio, PhD | Meet a Scientist

Dr. Sandra Cascio of Magee-Womens Research Institute is a 2021 recipient of OCRA’s Early Career Investigative Grant. With her project, “EGFL6 as a New Regulator of Myeloid Cell Expansion and Function in HGSOC,” Dr. Cascio seeks to better understand ovarian tumors’ microenvironments and, ultimately, to overcome ovarian cancer resistance to immunotherapy, opening up a new … Continued

Martin Cannon, PhD | Meet a Scientist

Martin Cannon, PhD | Meet a Scientist

Dr. Martin Cannon, of University of Arkansas for Medical Sciences (UAMS), is a 2021 recipient of OCRA’s Collaborative Research Development Grant. With his project, “Understanding and Targeting Myeloid Populations in Ovarian Cancer,” Dr. Cannon seeks to better understand the behavior of a type of immune cell that currently helps ovarian cancer tumors grow, in order … Continued

First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer

First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer

The following is a press release from Ovarian Cancer Research Alliance and Cancer Research Institute: NEW YORK, May 11, 2022 — The Cancer Research Institute (CRI) and Ovarian Cancer Research Alliance (OCRA) announced today that the first patients have been dosed in their new multi-center platform clinical trial testing novel cancer immunotherapy combinations in patients … Continued

Watch Now: What’s New in Ovarian Cancer Research and Treatment

Watch Now: What’s New in Ovarian Cancer Research and Treatment

Many exciting updates about progress against ovarian cancer were presented at this year’s Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer — the largest meeting of gynecologic cancer experts in the world. This April, gynecologic oncologist and ovarian cancer expert Dr. Sarah Adams joined OCRA for an interactive webinar reporting on the highlights (in … Continued

OCRA-Funded Study Pinpoints Partner Proteins That May Contribute to Ovarian Cancer Tumor Growth

OCRA-Funded Study Pinpoints Partner Proteins That May Contribute to Ovarian Cancer Tumor Growth

The interaction between two partner proteins may promote the growth of the most common ovarian cancer subtype, according to recent findings from OCRA-funded researchers at University of Pennsylvania and Cedars-Sinai Medical Center and their colleagues. The learnings, which were published in Science Signaling, may pave the way for the future development of new targeted therapies. HGSOC … Continued

New Immunotherapy Combination May Help Combat Ovarian Tumors

New Immunotherapy Combination May Help Combat Ovarian Tumors

A therapeutic strategy that targets key tumor proteins shows promise for treating the most common subtype of ovarian cancer, according to a recent study led by OCRA grantee Duygu Ozmadenci, PhD, of the University of California, San Diego Moores Cancer Center.  High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, with approximately 75% of epithelial ovarian cancers … Continued

Benoît Bragantini, PhD | Meet a Scientist

Benoît Bragantini, PhD | Meet a Scientist

Dr. Benoît Brangantini, of Mayo Clinic, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With his project, “Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM,” Dr. Bragantini aims to better understand how DNA damage and repair mechanisms can lead to ovarian cancer, and how these processes can be controlled to prevent ovarian … Continued

Highlights: 2022 Annual Meeting of the Society of Gynecologic Oncology (SGO)

Highlights: 2022 Annual Meeting of the Society of Gynecologic Oncology (SGO)

Submitted by ovarian cancer survivor Annie Ellis, OCRA Research Advocate and Scientific Advisory Committee member This year’s SGO annual meeting was held in Phoenix, Arizona from March 18-21. Approximately 2,100 medical professionals attended in person with several hundred more attending virtually to learn the latest on gynecologic cancers. By now, you may have seen professional coverage … Continued

Researchers Discover Genetic Link Between Ovarian Cancer Subtypes and Endometriosis

Researchers Discover Genetic Link Between Ovarian Cancer Subtypes and Endometriosis

Some ovarian cancers are genetically linked to the gynecologic disorder known as endometriosis, according to recent findings from an international team of researchers. Endometriosis is a disease in which tissue that normally lines the inside of the uterus — the endometrium — grows outside the uterus. Though endometriosis is classified as a benign disorder, it … Continued

Melanie Weigert, PhD | Meet a Scientist

Melanie Weigert, PhD | Meet a Scientist

Dr. Melanie Weigert, of University of Chicago, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With her project, “Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA,” Dr. Weigert aims to identify biomarkers that can predict how cancer cells will respond to platinum-based treatments, helping guide patients with potentially platinum-resistant cancer toward alternative therapies. Dr. Weigert’s … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.